新型肾脏保护药物对肾脏终点的影响为未来临床试验提供启示
该研究对CREDENCE、DAPA-CKD、FIDELIO-DKD和SONAR试验共4401、4304、5734和3668例患者进行事后分析,比较卡格列净、达格列净、非奈利酮和阿曲生坦对含不同eGFR下降阈值(40%、50%、57%)的复合肾脏终点的影响。结果显示,含较小eGFR下降阈值的终点事件率更高,但相对治疗效应与含57%下降的终点基本相似;含40%下降的复合终点所需样本量约为57%下降终点的一半。
要点
- 含40% eGFR下降的复合肾脏终点事件率高于含57%下降的终点。
- 四种药物对含40%或57% eGFR下降终点的相对效应基本相似,HR范围分别为0.63–0.82和0.59–0.76。
- 采用40% eGFR下降的复合终点所需样本量约为57%下降终点的一半。
核心结论
- 在CKD进展高风险人群中,新型肾脏保护治疗的相对效应在不同eGFR下降阈值的终点间似乎基本相似。
研究设计与样本
- 对CREDENCE(4401例)、DAPA-CKD(4304例)、FIDELIO-DKD(5734例)和SONAR(3668例)试验的事后分析。
- 评估卡格列净、达格列净、非奈利酮和阿曲生坦在慢性肾脏病患者中的效应。
- 比较活性药物与安慰剂对含不同eGFR下降阈值(40%、50%或57%)复合肾脏终点的影响,采用Cox比例风险回归模型。
主要发现
- 随访期间,含较小eGFR下降阈值的终点事件率高于含较大下降阈值的终点。
- 与对肾衰竭或肾衰竭死亡的治疗效应相比,含较小eGFR下降的复合终点的相对治疗效应幅度总体相似。
- 四种干预对含40% eGFR下降终点的风险比范围为0.63至0.82,对含57% eGFR下降终点的风险比范围为0.59至0.76。
- 含40% eGFR下降的复合终点临床试验所需参与者数量约为含57%下降终点的的一半,且统计效能相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Doubling of serum creatinine (equivalent to a 57% decline in the estimated glomerular filtration rate (eGFR)) is an accepted component of a composite kidney endpoint in clinical trials. Smaller declines in eGFR (40%, 50%) have been applied in several recently conducted clinical trials. Here, we assessed the effects of newer kidney protective agents on endpoints including smaller proportional declines in eGFR to compare relative event rates and the magnitude of observed treatment effects. We performed a post hoc analysis of 4401 patients in the CREDENCE, 4304 in the DAPA-CKD, 5734 in the FIDELIO-DKD, and 3668 in the SONAR trials, which assessed the effects of canagliflozin, dapagliflozin, finerenone and atrasentan in patients with chronic kidney disease. Effects of active therapies versus placebo on alternative composite kidney endpoints incorporating different eGFR decline thresholds (40%, 50%, or 57% eGFR reductions from baseline) with kidney failure or death due to kidney failure were compared. Cox-proportional hazards regression models were used to assess and compare treatment effects. During follow-up, event rates were higher for endpoints incorporating smaller versus larger eGFR decline thresholds. Compared to the treatment effects on kidney failure or death due to kidney failure, the magnitude of relative treatment effects was generally similar when considering composite endpoints incorporating smaller declines in eGFR. Hazard ratios for the four interventions ranged from 0.63 to 0.82 for the endpoint incorporating 40% eGFR decline and 0.59 to 0.76 for the endpoint incorporating 57% eGFR decline. Clinical trials incorporating a 40% eGFR decline in a composite endpoint would require approximately half the number of participants compared to a 57% eGFR decline with equivalent statistical power. Thus, in populations at high risk of CKD progression, the relative effects of newer kidney protective therapies appear generally similar across endpoints based on varying eGFR decline thresholds.
引用
- Heerspink HJL, Jongs N, Neuen BL, et al. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 2023. PMID: 37119876. doi:10.1016/j.kint.2023.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。